Three-tiered-copayment drug coverage and use of nonsteroidal anti-inflammatory drugs

Archives of Internal Medicine

Volumn 164, Issue 15, 2004, Pages 1679-1684

  Briesacher, Becky ^a   Kamal Bahl, Sachin ^b   Hochberg, Marc ^c,d   Orwig, Denise ^c   Kahler, Kristijan H ^d  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; GENERIC DRUG; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTHRITIS; ARTICLE; COMORBIDITY; DRUG CHOICE; DRUG COST; DRUG SELECTIVITY; DRUG USE; EMPLOYER; FEMALE; GASTROINTESTINAL DISEASE; HEALTH INSURANCE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; COMORBIDITY; COST SHARING; CYCLOOXYGENASE INHIBITORS; DRUGS, GENERIC; FEMALE; FORMULARIES; GASTROINTESTINAL DISEASES; HEALTH BEHAVIOR; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; REIMBURSEMENT, INCENTIVE; RETROSPECTIVE STUDIES; RISK; UNITED STATES;

EID: 3843051309     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.15.1679     Document Type: Article

References (41)

1. 2002 Annual Employer Health Benefits Survey. Washington, DC: Kaiser Family Foundation/Health Research & Educational Trust; 2003.
2. Penna P. Three-tier copay systems and consumer-centric care. J Manag Care Pharm. 2000;6:351-353.
3. Motheral B, Fairman KA. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care. 2001;39:1293-1304.
4. Joyce GF, Escarce JJ, Solomon MD, Goldman DP. Employer drug benefit plans and spending on prescription drugs [published correction appears in JAMA. 2002; 288:2409]. JAMA. 2002;288:1733-1739.
5. Joyce GF, Escarce JJ, Solomon MD, Goldman DP. Employer drug benefit plans and spending on prescription drugs [published correction appears in JAMA. 2002;288:2409]. JAMA. 2002;288:1733-1739.
6. Ernst ME, Kelly ME, Hoehns JD, et al. Prescription medication costs: a study of physician familiarity. Arch Fam Med. 2000;9:1002-1007.
7. Takeda Prescription Drug Benefit Cost and Plan Design Report. Lincolnshire, Ill: Pharmacy Benefit Management Institute; 2002.
8. Thomas CP, Wallack SS, Lee S, Ritter GA. Impact of health plan design and management on retirees' prescription drug use and spending, 2001. Health Aff (Millwood). 2002;Supp Web Exclusives:W408-W419.
9. Rector TS, Finch MD, Danzon PM, Pauly MV, Manda BS. Effect of tiered prescription copayments on the use of preferred brand medications. Med Care. 2003;41:398-406.
10. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol. 1987;82:1153-1158.
11. Singh G, Ramey DR, Morfield D, Shi H, Hatoum HT, Fries JF. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: a prospective observational cohort study. Arch Intern Med. 1996;156:1530-1536.
12. Hawkey CJ. Non-steroidal anti-inflammatory drugs and peptic ulcers [published correction apears in BMJ. 1990;300:764]. BMJ. 1990;300:278-284.
13. Hawkey CJ. Non-steroidal anti-inflammatory drugs and peptic ulcers [published correction apears in BMJ. 1990;300:764]. BMJ. 1990;300:278-284.
14. Goldstein J. Significant upper gastrointestinal events associated with conventional NSAID versus celecoxib. J Rheumatol Suppl. 2000;60:25-28.
15. Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs [published correction appears in Lancet. 1994;343:1302]. Lancet. 1994;343:1075-1078.
16. Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs [published correction appears in Lancet. 1994;343:1302]. Lancet. 1994;343:1075-1078.
17. Soll AH, Weinstein WM, Kurata J, McCarthy D. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med. 1991;114:307-319.
18. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med. 1991;115:787-796.
19. Garcia Rodriguez L, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs [published correction appears in Lancet. 1994;343:1048]. Lancet. 1994;343:769-772.
20. Garcia Rodriguez L, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs [published correction appears in Lancet. 1994;343:1048]. Lancet. 1994;343:769-772.
21. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med. 1998;105(suppl 1B):31S-38S.
22. Fries JF. NSAID gastropathy: epidemiology. J Musculoskel Med. 1991;8:21-28.
23. Day R, Morrison B, Luza A, et al. for the Rofecoxib/Ibuprofen Comparator Study Group. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med. 2000;160:1781-1787.
24. Makarowski W, Zhao WW, Bevirt T, Reckert DP. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage. 2002;10:290-296.
25. Schnitzer TJ, Hochberg MC. COX-2-selective inhibitors in the treatment of arthritis. Cleve Clin J Med. 2002;69(suppl 1):SI20-SI30.
26. Goldstein JL, Silverstein FE, Agrawal NM, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol. 2000;95:1681-1690.
27. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systemic review of randomised controlled trials. BMJ. 2002;325:619-623.
28. Bombardier C, Laine L, Reicin A, et al. VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520-1528.
29. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS Study: a randomized controlled trial. JAMA. 2000;284:1247-1255.
30. Goldstein JL, Correa P, Zhao WW, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol. 2001;96:1019-1027.
31. Bensen W, Weaver A, Espinoza L, et al. Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen. Rheumatology (Oxford). 2002:41:1008-1016.
32. Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med. 2000;160:2998-3003.
33. Maetzel A, Krahn MD, Naglie G. Economic Assessment: Celecoxib and Rofecoxib for Patients With Osteoarthritis or Rheumatoid Arthritis. Ottawa, Ontario: Canadian Coordinating Office for Health Technology Assessment; 2002. Technology Overview No. 6.
34. National Institute for Clinical Excellence. Guidance on the Use of Cyclooxygenase (Cox) II Selective Inhibitors, Celecoxib, Rofecoxib, Meloxicam and Etodolac for Osteoarthritis and Rheumatoid Arthritis. London, England: National Institute for Clinical Excellence; July 2001.
35. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum. 2000;43:1905-1915.
36. Simon L, Lipman A, Jacox A, et al. Guideline for the Management of Arthritis Pain in Osteoarthritis, Rheumatoid Arthritis, and Juvenile Chronic Arthritis. Glenview, Ill: American Pain Society; 2002. APS Clinical Practice Guidelines Series, No. 2.
37. Kanavos P, Reinhardt U. Reference pricing for drugs: is it compatible with U.S. health care? Health Aff (Millwood). 2003;22:16-30.
38. Hochberg MC. COX-2: where are we in 2003? be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients. Arthritis Res Ther. 2003;5:28-31.
39. Simon LS, Smolen JS, Abramson SB, et al. Controversies in COX-2 selective inhibition. J Rheumatol. 2002;29:1501-1510.
40. Simon LS, Hatoum HT, Bittman RM, Archambault WT, Polisson RP. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Fam Med. 1996;28:204-210.
41. Fendrick AM. Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy. Cleve Clin J Med. 2002;69 (suppl 1):SI59-SI64.